Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. insider Ian T. Clark filed notice of a proposed sale of 14,180 shares of common stock, with an aggregate market value of $2,253,450.00, to be sold on or about 08/04/2026 through Charles Schwab & Co., Inc. on NASDAQ. Guardant Health had 134,196,170 shares of common stock outstanding in connection with this notice. During the prior three months, Clark sold 6,876 shares on 05/20/2026 for $735,049.00, and the filing lists planned transactions tied to restricted stock lapse and an employee stock option exercise.
Guardant Health, Inc., a precision oncology company, has filed an automatic shelf registration as a well-known seasoned issuer. The shelf registration allows Guardant to offer from time to time primary securities, including common stock, preferred stock, debt securities, depositary shares, warrants, purchase contracts and units, in one or more offerings. It also registers the resale of shares of common stock held by selling stockholders, and Guardant will not receive proceeds from those resale transactions. Net proceeds from any primary offerings will be used as described in the applicable prospectus supplements. Guardant’s common stock trades on the Nasdaq Global Select Market under the symbol “GH,” and the last reported sale price was $144.07 per share on July 29, 2026. The company is incorporated in Delaware and is a leading provider of blood and tissue tests, real-world data and AI analytics for cancer screening, monitoring and treatment selection.
Guardant Health, Inc. reported rapid top-line growth but continued losses for the three and six months ended June 30, 2026. Q2 revenue was $334,978 (thousands) versus $232,088 (thousands) a year earlier, driven by oncology revenue of $219,105 (thousands) (prior-year $158,685) and screening revenue of $52,866 (thousands) (prior-year $14,814). Net loss for Q2 was $120,142 (thousands), or $0.90 per share, compared with $99,899 (thousands); for the first half, net loss was $232,217 (thousands) on revenue of $636,643 (thousands) versus $435,559 (thousands).
As of June 30, 2026, cash and cash equivalents were $1,053,469 (thousands) and restricted cash was $114,270 (thousands), with no short-term marketable securities, while long-term convertible senior notes had a net carrying amount of $1,502,943 (thousands). Stockholders’ deficit widened to $222,867 (thousands), reflecting an accumulated deficit of $3,226,729 (thousands) and 133.6 million common shares outstanding at quarter-end.
The company describes a broad precision oncology and screening portfolio, including FDA-approved Guardant360 CDx tests and the Shield blood test for colorectal cancer screening, which has FDA approval, Medicare coverage and guideline inclusion. Legal contingencies include a patent verdict in favor of TwinStrand Biosciences and the University of Washington, for which Guardant has recorded an $83.4 million liability and disclosed an estimated possible loss range through June 30, 2026 of zero to $250 million.
Guardant Health reported second-quarter 2026 revenue of $335.0 million, up 44% year over year, led by oncology revenue of $219.1 million and screening revenue of $52.9 million, which grew over 250%. Total oncology tests reached about 104,000, while Shield screening tests increased to about 66,000. Non-GAAP gross margin improved to 67%.
GAAP net loss widened to $120.1 million (‑$0.90 per share), with non-GAAP net loss of $56.2 million and free cash flow of ‑$69.5 million. Cash, cash equivalents and restricted cash were $1.2 billion as of June 30, 2026.
The company raised full‑year 2026 revenue guidance to $1.34–$1.36 billion, implying 36%–38% growth, with higher expected oncology and Shield volumes. Recent milestones include multiple FDA approvals for Guardant360 assays, Shield’s inclusion in American Cancer Society colorectal screening guidelines, and initial commercial coverage for Shield from UnitedHealth Group.
BlackRock, Inc. filed an amended Schedule 13G reporting its passive ownership of common stock of Guardant Health, Inc. BlackRock beneficially owns 6,895,256 shares, representing 5.2% of Guardant Health’s outstanding common stock.
BlackRock reports sole voting power over 6,667,643 shares and sole dispositive power over 6,895,256 shares, with no shared voting or dispositive power. Various underlying clients and investors may receive dividends or sale proceeds, but no single person has more than five percent of Guardant Health’s outstanding common shares.
Guardant Health director Roberto Mignone exercised a restricted stock unit award on July 21, 2026, converting 264 Restricted Stock Units into 264 shares of Common Stock at $0.00 per share. Following this transaction, he directly holds 9,746 Common shares and 7,128 Restricted Stock Units. The RSU grant, awarded on November 8, 2024, vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the subsequent three years. The transaction was not marked as made under a Rule 10b5-1 trading plan, as the related checkbox was left unchecked.
Guardant Health, Inc. director Manuel Hidalgo Medina reported the vesting and settlement of 232 Restricted Stock Units into 232 shares of common stock on July 17, 2026. After these transactions he directly holds 5,306 common shares and 5,569 remaining RSUs from a four-year grant awarded July 17, 2024.
Guardant Health director Tariq Musa reported transactions in company equity. On July 15, 2026, he converted 250 Restricted Stock Units into 250 shares of common stock at no cash cost, leaving 1,999 RSUs outstanding. On July 16, he sold 116 shares of common stock in an open-market sale at $163.29 per share and held 11,182 shares afterward.
Guardant Health, Inc. shareholder Musa Tariq is reported in a Form 144 as intending to sell an amount of 116 common shares through Charles Schwab & Co., Inc. on NASDAQ, with a referenced value of $18,942.00 and an associated date of July 16, 2026.
These securities are described as common stock acquired on July 15, 2026 via a Restricted Stock Lapse, categorized as Equity Compensation. The filing also lists securities sold during the past three months: amounts of 116 with dollar values of $9,840.00, $11,131.00 and $15,102.00 on April 16, May 18 and June 16, 2026, and an amount of 1,951 with a dollar value of $255,893.00 on June 22, 2026.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity tied to restricted stock units (RSUs). On 2026-07-01, several RSU awards vested and converted into a total of 7,063 shares of Guardant Health common stock at a stated price of $0.00 per share.
To cover tax obligations from this vesting, the company retained 3,707 shares at a price of $170.77 per share, according to the filing footnotes. These transactions reflect RSU vesting, derivative exercises, and tax withholding, not open-market purchases or sales.